

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2022/251441 A1

(43) International Publication Date
01 December 2022 (01.12.2022)

(51) International Patent Classification:

A61P 35/00 (2006.01) *A61K 31/496* (2006.01)
A61K 39/00 (2006.01) *A61K 31/573* (2006.01)
A61K 31/4412 (2006.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(21) International Application Number:

PCT/US2022/031055

(22) International Filing Date:

26 May 2022 (26.05.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/194,026 27 May 2021 (27.05.2021) US

(71) Applicants: **CELGENE CORPORATION** [US/US]; 86 Morris Avenue, Summit, NJ 07901 (US). **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; Route 206 and Province Line Road, Princeton, NJ 08543 (US).

(72) Inventors: **MACIAG, Paulo, Cesar**; c/o Bristol-Myers Squibb Company, 86 Morris Avenue, Summit, NJ 07901 (US). **PELUSO, Teresa**; c/o Celgene Srl, Piazzale Dell'Industria 40-46, 00144 Rome (IT).

(74) Agent: **BRUNER, Michael, J.** et al.; Jones Day, 250 Vesey Street, New York, NY 10281-1047 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS OF TREATING MULTIPLE MYELOMA USING COMBINATION THERAPY

(57) Abstract: Provided herein are methods of using (S)-4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoin-dolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, in combination with a second active agent provided herein for treating, preventing or managing multiple myeloma.

WO 2022/251441 A1